Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kanwaljit Gill

Cardiovascular Disease Palmdale, CA Medical Doctor

NPI 1477612752 CMS profile 111975

38656 Medical Center Drive, Suite A, Palmdale, CA 93551

Open in the dashboard

General payments

$15,332

568 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kanwaljit Gill of Palmdale, CA is reported in the CMS Open Payments database as having received $15,332 across 568 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,696 121
2024 General $2,211 91
2023 General $1,858 86
2022 General $2,846 48
2021 General $1,641 78
2020 General $759 51
2019 General $2,321 93

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kanwaljit Gill
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Kanwaljit Gill were reported at $3,696. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Kanwaljit Gill Cardiovascular Disease median Middle half National median
2019 $2,321 $450 $127–$1,392 $163
2020 $759 $242 $77–$751 $114
2021 $1,641 $335 $101–$1,037 $132
2022 $2,846 $395 $121–$1,211 $149
2023 $1,858 $443 $136–$1,283 $160
2024 $2,211 $450 $136–$1,323 $164
2025 $3,696 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $2,325 30 payments
  2. AstraZeneca Pharmaceuticals LP $1,995 73 payments
  3. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $1,916 92 payments
  4. Biotronik Inc. $1,143 25 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $995 55 payments
  6. Abiomed $667 19 payments
  7. Merck Sharp & Dohme Corporation $551 26 payments
  8. Amgen Inc. $535 26 payments
  9. Shockwave Medical, Inc $530 8 payments
  10. Novartis Pharmaceuticals Corporation $512 28 payments
  11. Other $4,163 186 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,939 556 payments
  2. Travel and Lodging $2,163 6 payments
  3. Education $229 6 payments
Products named General payments · program years 2019–2025
  1. LifeVest $1,916 92 payments
  2. VersaCross Access Solution $1,652 5 payments
  3. BRILINTA $985 20 payments
  4. FARXIGA $742 41 payments
  5. VERQUVO $565 27 payments
  6. Impella $509 14 payments
  7. XARELTO $458 18 payments
  8. JARDIANCE Diabetes $420 23 payments
  9. JARDIANCE Diabetes $417 23 payments
  10. Repatha $393 18 payments
  11. Other $7,336 348 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 76 drugs

Part D claims

4,942

Median for Cardiology: 2,533

Drug cost

$1,618,810

Median for Cardiology: $485,213

Branded share of claims

32%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 313 $404,234
Entresto Sacubitril/Valsartan Brand 222 $285,580
Tyvaso Refill Kit Treprostinil/Neb Accessories Brand 14 $280,552
Opsumit Macitentan Brand 12 $147,769
Jardiance Empagliflozin Brand 113 $140,737
Xarelto Rivaroxaban Brand 88 $94,773
Farxiga Dapagliflozin Propanediol Brand 68 $65,290
Repatha Sureclick Evolocumab Brand 57 $52,349
Brilinta Ticagrelor Brand 47 $44,449
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 25 $18,492

The 10 drugs with the highest cost, of 76 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 93 billing codes

Paid by Medicare

$769,214

Of which drugs: $575

Medicare patients

1,715

Average age 74

Services billed

6,933

922 women, 793 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Diabetes 51%
Heart failure 40%
Ischemic heart disease 40%
Chronic kidney disease 35%
COPD 33%
Atrial fibrillation 31%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 95 95 $525
Infusion, normal saline solution, 250 cc J7050 Office 98 98 $51

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $220
$220 113 —
XARELTO
  • Janssen Pharmaceuticals, Inc $189
$189 88 —
VERQUVO
  • Merck Sharp & Dohme Corporation $170
$170 — —
Repatha
  • Amgen Inc. $97
$97 57 —
ONPATTRO
  • Alnylam Pharmaceuticals Inc. $83
$83 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

568 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record